Back to Journals » Cancer Management and Research » Volume 2

Optimal management of cancer anorexia–cachexia syndrome

Authors Argiles JM, Olivan Mireia, Busquets S, Lopez-Soriano FJ

Published 22 January 2010 Volume 2010:2 Pages 27—38

DOI https://doi.org/10.2147/CMAR.S7101

Review by Single-blind

Peer reviewer comments 4


Josep M Argilés, Mireia Olivan, Sílvia Busquets, Francisco Javier López-Soriano

Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain

Abstract: According to a recent consensus, cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the majority of cancer patients before death and it is responsible for the deaths of 22% of cancer patients. Although bodyweight is the most important endpoint of any cachexia treatment, body composition, physical performance and quality of life should be monitored. From the results presented here, one can speculate that a single therapy may not be completely successful in the treatment of cachexia. From this point of view, treatments involving different combinations are more likely to be successful. The objectives of any therapeutic combination are two-fold: an anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective leading to the synthesis of macromolecules such as contractile proteins.
Keywords: wasting, cancer, anorexia, nutraceuticals, drugs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]